Returning guest, Nelson Ambrogio, Senior Vice President and General Manager Oncology, Bayer Pharmaceuticals US, discusses the FDA approval of NUBEQA ® (darolutamide) in combination with docetaxel for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC). He talks about what this approval means for those living with prostate cancer and the current treatment landscape, what’s next for NUBEQA, and the future of Bayer in oncology.

Nelson is a highly respected and dynamic global business leader who is dedicated to delivering innovative health care solutions to enhance people’s lives.

As the Head of the Bayer US Oncology franchise, Nelson is responsible for leading the US Sales and Marketing teams, and overseeing a portfolio of six therapies across a range of indications. Oncology is one of Bayer’s global strategic pillars, playing a fundamental role in positioning Bayer as a science leader in key areas of innovation, while realizing sustainable growth. In his current role, Nelson is a member of the Bayer Pharmaceuticals Leadership Team in the US and in the Americas.

Prior to his appointment in Oncology, Nelson was Head of the Women’s Healthcare Business Unit in the US. A multi-national healthcare executive with broad experience transforming large, complex organizations, Nelson’s career spans more than 20 years with Bayer and Schering. Nelson has held a range of leadership positions around the world, including the US, Europe, Asia/Pacific and Latin America.

Nelson resides in New Jersey with his wife and four children.

Liked it? Take a second to support healthprofessionalradio on Patreon!